De som köpt den här boken har ofta också köpt Power and Progress av Simon Johnson, Daron Acemoglu (häftad).
Köp båda 2 för 1669 kr". . . the book edited by Gatsonis and Morton fills a gap and seems very valuable for applied statisticians interested in the field of comparative effectiveness research particularly due to the selection of relevant topics and the scientific quality of the individual chapters written by leaders in the field." ~Christian Stock, Biometrical Journal "In summary, the book covers a wide range of topics in CER with a good balance of methodology and practical considerations. Given that CER is a fast-growing area and is relatively unfamiliar to pharmaceutical statisticians, this book will be useful either as a general reference for those working in medical affairs or health technology assessment, or for those looking for a short introduction to a specific method (e.g., NMA)... In general, the book is quite readable without much prerequisite for statistical knowledge and will be useful to applied statisticians who are working in relevant areas or have an interest in CER." ~Pharmaceutical Statistics
Constantine Gatsonis is Henry Ledyard Goddard University Professor, Chair of the Department of Biostatistics, and founding Director of the Center for Statistical Sciences at the Brown University School of Public Health. Dr. Gatsonis is a Fellow of the American Statistical Association (ASA) and received a Long-Term Excellence Award from the Health Policy Statistics Section of ASA. Sally C. Morton is Dean of the College of Science at Virginia Tech. Previously, she was Professor and Chair of the Department of Biostatistics in the Graduate School of Public Health, and Director of the Comparative Effectiveness Research Center in the Health Policy Institute, at the University of Pittsburgh. Dr. Morton is a Fellow and past president of the ASA and received the association's Founders Award.
Observational studies. Data sources and design considerations for observational studies in CER. Causal inference methods in CER. Clinical trials in CER. CER considerations for clinical trials: Choice of research questions, populations, study settings, and endpoints. Approaches to randomization: cluster randomization, use of EMR. Adaptive designs, Bayesian methods. Deriving evidence for population subsets, CER and personalized medicine. Systematic reviews. General: systematic reviews with study-level and individual patient-level data. General: Strength and quality of evidence data. Network meta-analysis. Systematic reviews of diagnostic accuracy. Modeling. Decision analysis. Micro simulation methods. Cost-effectiveness analysis. Value of Information analysis. CER for diagnostic tests. Prevention studies. Early detection and surveillance studies.